Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 versus platinum doublet chemotherapy in EGFR-mutated advanced nonsquamous NSCLC after prior EGFR TKI
2023-504910-31-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan, pemetrexed and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall survival. Planned start Jul 2024; status: authorised.
02
Drugs
sacituzumab tirumotecanpemetrexedcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-504910-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504910-31-00.